Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results

Abstract

Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at‐risk infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD‐02, that identifies infants with a genetic high risk of T1D, enrolls these into primary prevention trials, and follows the children for beta‐cell autoantibodies and diabetes. Genetic testing is offered either at delivery, together with the regular newborn testing, or at a newborn health care visits before the age of 5 months in regions of Germany (Bavaria, Saxony, Lower Saxony), UK (Oxford), Poland (Warsaw), Belgium (Leuven), and Sweden (Region Skåne). Seven clinical centers will screen around 330 000 infants. Using a genetic score based on 46 T1D susceptibility single‐nucleotide polymorphisms (SNPs) or three SNPS and a first‐degree family history for T1D, infants with a high (>10%) genetic risk for developing multiple beta‐cell autoantibodies by the age of 6 years are identified. Screening from October 2017 to December 2018 was performed in 50 669 infants. The prevalence of high genetic risk for T1D in these infants was 1.1%. Infants with high genetic risk for T1D are followed up and offered to participate in a randomized controlled trial aiming to prevent beta‐cell autoimmunity and T1D by tolerance induction with oral insulin. The GPPAD‐02 study provides a unique path to primary prevention of beta‐cell autoimmunity in the general population. The eventual benefit to the community, if successful, will be a reduction in the number of children developing beta‐cell autoimmunity and T1D.

Osteoarthritis year in review 2019: genetics, genomics and epigenetics

“…Identification of genetic loci using hypothesis-free genome wide association studies (GWAS) has given novel insights into diseases 4e6 , identified potential drug targets 7 , and led to the use of polygenic risk scores in selecting individuals for clinical trials 8 . However, until recently, identification of OA loci was trailing behind other complex diseases and phenotypes such as rheumatoid arthritis (over 100 risk loci; 9 ) and height (over 3,000 loci; 10 ), with only 19 OA loci reported up to April 2017 at genome wide significance level of P 5 Â 10 À8 (Fig.…”

Next steps in the identification of gene targets for type 1 diabetes

“…It is likely that population screening will use a combination of genetics with emergent risk factor testing to determine those eligible for intervention (e.g. intervention trials prior to disease onset, such as with oral insulin therapy) and is being tested now [47]. With the ever-expanding reliance on the merger of electronic health records with biobanks, these research directions could be directly applied to prediction, intervention and treatment in diverse and previously underserved populations.…”

Typ-1-Diabetes: Früherkennung und Ansätze zur Prävention

“…Eine Risikostratifizierung ermöglicht es, Kinder mit einem gegenüber der Allgemeinbevölkerung 25-fach höheren Risiko eines Frühstadiums oder manifesten Diabetes bereits im Kleinkindalter zu ermitteln. Die betroffenen Familien werden zum Diabetesrisiko beraten, und die Teilnahme an einer Primärpräventionsstudie mit oralem Insulin wird angeboten [ 35 ].…”